West Pharmaceutical Services (WST) Income from Continuing Operations (2009 - 2026)

West Pharmaceutical Services (WST) has reported Income from Continuing Operations for 18 consecutive years, with 147900000.0 the latest figure, recorded in Q2 2026.

• Quarterly Income from Continuing Operations rose 16.64% year-over-year to 147900000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 549400000.0 (up 16.05% YoY) and the FY2025 annual result came in at 479300000.0, changed 0.27% from the prior year.
• Income from Continuing Operations rose to 147900000.0 in Q2 2026 per WST's latest filing, from 135400000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for WST reached as high as 183000000.0 in Q2 2022 and fell as low as 86400000.0 in Q1 2025.
• A 5-year average of 132305555.56 and a median of 132900000.0 in 2023 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 32.43% — and 2026, when it surged 56.71%.
• Year by year, Income from Continuing Operations stood at 99800000.0 in 2022, then surged by 33.97% to 133700000.0 in 2023, then fell by 4.19% to 128100000.0 in 2024, then climbed by 0.08% to 128200000.0 in 2025, then increased by 15.37% to 147900000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 147900000.0, 135400000.0, and 128200000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.